GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » PB Ratio

Moleculin Biotech (Moleculin Biotech) PB Ratio : 0.53 (As of May. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-25), Moleculin Biotech's share price is $4.93. Moleculin Biotech's Book Value per Share for the quarter that ended in Mar. 2024 was $9.34. Hence, Moleculin Biotech's PB Ratio of today is 0.53.

The historical rank and industry rank for Moleculin Biotech's PB Ratio or its related term are showing as below:

MBRX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 5.62
Current: 0.55

During the past 9 years, Moleculin Biotech's highest PB Ratio was 5.62. The lowest was 0.00. And the median was 0.00.

MBRX's PB Ratio is ranked better than
92% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs MBRX: 0.55

During the past 12 months, Moleculin Biotech's average Book Value Per Share Growth Rate was -59.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -16.90% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Moleculin Biotech was -2.70% per year. The lowest was -34.80% per year. And the median was -20.30% per year.

Back to Basics: PB Ratio


Moleculin Biotech PB Ratio Historical Data

The historical data trend for Moleculin Biotech's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech PB Ratio Chart

Moleculin Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only 2.69 3.11 0.67 0.58 1.10

Moleculin Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.43 0.36 1.10 0.63

Competitive Comparison of Moleculin Biotech's PB Ratio

For the Biotechnology subindustry, Moleculin Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's PB Ratio distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's PB Ratio falls into.



Moleculin Biotech PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Moleculin Biotech's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=4.93/9.339
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Moleculin Biotech  (NAS:MBRX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Moleculin Biotech PB Ratio Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Moleculin Biotech (Moleculin Biotech) Business Description

Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.
Executives
Jonathan P. Foster officer: Exec. Vice President and CFO 2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp director, 10 percent owner, officer: Chairman and Acting CEO 1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco director PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker 10 percent owner, officer: President and COO
Michael D Cannon director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth officer: Chief Financial Officer 2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380

Moleculin Biotech (Moleculin Biotech) Headlines

From GuruFocus

Moleculin Reports First Quarter 2023 Financial Results

By PRNewswire PRNewswire 05-11-2023